Division of Vascular Surgery, Department of Surgery, State University of New York at Buffalo, Buffalo, NY; Division of Vascular Surgery, VA Western NY Healthcare System, Buffalo, NY.
Division of Vascular Surgery, Department of Surgery, State University of New York at Buffalo, Buffalo, NY; Division of Vascular Surgery, VA Western NY Healthcare System, Buffalo, NY.
J Vasc Surg. 2019 Jun;69(6):1736-1746. doi: 10.1016/j.jvs.2018.10.054. Epub 2018 Dec 24.
Pre-emptive selective embolization of inferior mesenteric artery (IMA), lumbar arteries (LAs), and perigraft sac for prevention of type II endoleak (T2EL) has not been widely adopted. We perform pre-emptive nonselective perigraft aortic sac embolization with coils (PNPASEC) in patients at high risk for development of T2EL (four or more patent LAs, patent IMA ≥3 mm, and ≥30-mm aortic flow lumen). The goal of this study was to see whether PNPASEC decreases T2ELs requiring reinterventions.
All 266 patients undergoing elective endovascular aneurysm repair between September 1, 2007, and October 31, 2015, were retrospectively evaluated from a prospectively maintained database. Patients (N = 212; 211 men) with preoperative and postoperative contrast-enhanced computed tomography scans were included. Our PNPASEC technique involves leaving a wire in the sac after cannulation of the contralateral gate and inserting large (0.035-inch) coils into the sac after bifurcated graft deployment. T2EL and reintervention rates were compared between patients who underwent PNPASEC (group I) and those who met the criteria but did not have PNPASEC (group II) and those who did not meet the criteria (Group III).
Forty-seven (22.2%) patients were PNPASEC candidates and 165 (77.8%) patients (group III) were not. Among PNPASEC candidates, 16 (7.5%) underwent PNPASEC (group I) and 31 (14.6%) did not (group II). There were no significant differences between groups in terms of comorbidities, aneurysm size, and anatomic and neck characteristics. Mean number of patent LAs was similar between group I (4.5 ± 0.8) and group II (4.5 ± 0.9), which was significantly greater than in group III (1.9 ± 1.3; P < .001); 43.6% of group III patients had patent IMA. Mean follow-up was 44 ± 25 months. T2EL at 6 months was observed in 48.4% in group II, 3.0% in group III, and 6.3% in group I (P < .001). Sac diameter increase was seen in 38.7% in group II vs 6.1% in group III and 6.3% in group I (P < .001), with complete sac shrinkage in 23.3% in group II vs 23.8% in group III and 50.0% in group I (P = .09). T2EL-related interventions were performed in 29.0% in group II vs 1.2% in group III and 6.3% in group I (P < .001). Any endoleak at last follow-up was seen in 25.8% in group II vs 2.4% in group III and none in group I (P < .001).
Nonselective perigraft sac coil embolization in patients at high risk for T2EL (20% of patients undergoing endovascular aneurysm repair) is effective in preventing development of T2EL and is associated with decrease in sac size and reintervention rates.
对于有发生 II 型内漏(T2EL)风险的患者(有 4 个或以上通畅的腰动脉、肠系膜下动脉≥3mm 或≥30mm 主动脉血流腔),我们采用预防性的非选择性支架外囊区主动脉瘤腔内栓塞术(PNPASEC)进行选择性肠系膜下动脉、腰动脉栓塞和瘤囊栓塞,以预防 T2EL 的发生。本研究旨在观察 PNPASEC 是否能降低需要再次介入治疗的 T2EL。
我们从一个前瞻性维护的数据库中回顾性评估了 2007 年 9 月 1 日至 2015 年 10 月 31 日期间接受择期血管内动脉瘤修复术的所有 266 例患者。纳入了术前和术后均行增强 CT 扫描的患者(N=212;211 名男性)。我们的 PNPASEC 技术包括在对侧入路血管腔内导管插入后在瘤囊内留置导丝,在分叉型移植物放置后将大(0.035 英寸)的线圈插入瘤囊内。比较了行 PNPASEC(I 组)、符合但未行 PNPASEC(II 组)和不符合(III 组)标准的患者的 T2EL 和再次介入治疗率。
47 例(22.2%)患者为 PNPASEC 候选者,165 例(77.8%)患者(III 组)不符合条件。在 PNPASEC 候选者中,16 例(7.5%)患者行 PNPASEC(I 组),31 例(14.6%)未行(II 组)。I 组和 II 组在合并症、动脉瘤大小、解剖和颈部特征方面无显著差异。I 组(4.5±0.8)和 II 组(4.5±0.9)的通畅腰动脉数量相似,明显多于 III 组(1.9±1.3;P<0.001);43.6%的 III 组患者有肠系膜下动脉通畅。平均随访时间为 44±25 个月。6 个月时,II 组 T2EL 发生率为 48.4%,III 组为 3.0%,I 组为 6.3%(P<0.001)。II 组的瘤囊直径增大发生率为 38.7%,III 组为 6.1%,I 组为 6.3%(P<0.001),II 组完全瘤囊缩小发生率为 23.3%,III 组为 23.8%,I 组为 50.0%(P=0.09)。II 组 T2EL 相关介入治疗发生率为 29.0%,III 组为 1.2%,I 组为 6.3%(P<0.001)。最后一次随访时任何内漏的发生率在 II 组为 25.8%,在 III 组为 2.4%,在 I 组为 0(P<0.001)。
对于有发生 T2EL 风险的患者(20%的血管内动脉瘤修复术患者),采用非选择性支架外囊区主动脉瘤腔内栓塞术(PNPASEC)是有效的,可以预防 T2EL 的发生,并与瘤囊体积缩小和再次介入治疗率降低相关。